Intra-Cellular Therapies, Inc.
ITCIDelisted Apr 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
Q1 2023 vs. Q4 2022
How the institutions holding Intra-Cellular Therapies, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 283 | 2 | 274 | −7 |
| Shares | 83.3M | 311 | 83.9M | +559.1K (+0.7%) |
| Value | $4.41B | $16.4K | $4.55B | +$138.0M (+3.1%) |
2 institutions that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (37)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
Sold out (44)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
Not filed for Q1 2023 yet (2)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| HealthInvest Partners AB | 292 | $15.5K |
| Cornerstone Planning Group LLC | 19 | $908 |